These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19806427)

  • 21. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
    Pietras RJ
    Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
    Johnston SR; Lu B; Dowsett M; Liang X; Kaufmann M; Scott GK; Osborne CK; Benz CC
    Cancer Res; 1997 Sep; 57(17):3723-7. PubMed ID: 9288779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor: current understanding of its activation and modulation.
    Osborne CK; Schiff R; Fuqua SA; Shou J
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PubMed ID: 11916222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What clinicians need to know about antioestrogen resistance in breast cancer therapy.
    Milano A; Dal Lago L; Sotiriou C; Piccart M; Cardoso F
    Eur J Cancer; 2006 Nov; 42(16):2692-705. PubMed ID: 16963260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aromatase inhibitors: future directions.
    Osborne CK; Schiff R
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):183-7. PubMed ID: 16019204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.
    Yang X; Yang S; McKimmey C; Liu B; Edgerton SM; Bales W; Archer LT; Thor AD
    Carcinogenesis; 2010 Apr; 31(4):695-702. PubMed ID: 20067990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to endocrine therapy in breast cancer.
    Kurebayashi J
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways.
    Saggar JK; Chen J; Corey P; Thompson LU
    Mol Nutr Food Res; 2010 Mar; 54(3):415-25. PubMed ID: 19904759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex hormone receptors in breast cancer.
    D'Abreo N; Hindenburg AA
    Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Epidermal growth factor receptor as a prognostic factor of breast cancers].
    Tsutsui S
    Nihon Rinsho; 2000 Apr; 58 Suppl():442-7. PubMed ID: 11026031
    [No Abstract]   [Full Text] [Related]  

  • 38. [Biomarkers of endocrine therapy-resistance in breast cancers].
    de Cremoux P; Debled M; Bonnefoi H; Cottu P
    Bull Cancer; 2010 Aug; 97(8):951-63. PubMed ID: 20605764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.
    Roop RP; Ma CX
    Future Oncol; 2012 Mar; 8(3):273-92. PubMed ID: 22409464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
    Osborne CK; Shou J; Massarweh S; Schiff R
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):865s-70s. PubMed ID: 15701879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.